Therapeutic Response Statement (Sensitivity)

This therapeutic response statement Supports the relationship that MET Exon 14 (Deletion) status confers therapeutic sensitivity to Capmatinib in patients with Non-Small Cell Lung Cancer.

Health Canada approved capmatinib for the treatment of adult patients with locally advanced unresectable or metastatic non-small cell lung cancer (NSCLC) harbouring mesenchymal-epithelial transition (MET) exon 14 skipping alterations.

This statement is based on a regulatory approval from the Health Canada:

TABRECTA (capmatinib tablets) is indicated for the treatment of adult patients with locally advanced unresectable or metastatic non-small cell lung cancer (NSCLC) harbouring mesenchymal-epithelial transition (MET) exon 14 skipping alterations.

Citation

Novartis Pharmaceuticals Canada Inc. Tabrecta (capmatinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00071417.PDF. Revised June 2023. Accessed June 2025.

Contributions

Date	Contributor	Description
2024-10-30	Van Allen lab	Initial access of FDA approvals